Sublingual Immunotherapy (Grazax®)

Assessment Status Rapid review complete
Drug Sublingual Immunotherapy
Brand Grazax®
Indication For the Prevention of Seasonal Grass Pollen-Induced Rhinoconjunctivitis.
Assessment Process
Rapid review commissioned 01/09/2007
Rapid review completed 24/09/2007
Rapid review outcome Reimbursement not recommended

The cost-effectiveness of Grazax® remains to be established and this product cannot be recommended as value for money at this point in time.

Technical Summary